Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Late-onset schizophrenia 

Late-onset schizophrenia
Chapter:
Late-onset schizophrenia
Author(s):

Sarah Brunelle

, Ipsit V. Vahia

, and Dilip V. Jeste

DOI:
10.1093/med/9780199644957.003.0046
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 January 2021

Although schizophrenia with onset in middle or late-life is a relatively uncommon, a considerable proportion of patients do experience the first manifestations of the disease after the age of forty. The current nomenclature utilizes terminology based on age at onset: late-onset schizophrenia (LOS) for illness with onset between ages 40 and 60, and very-late-onset schizophrenia-like psychosis (VLOSLP) for onset after age 60. Recent evidence suggests more similarities than differences in epidemiology, etiology or risk factors and clinical presentation between these clinical entities, although a later onset seems to be associated with better premorbid functioning and female gender. Relatively stable cognitive deficits are observed in patients regardless of age at onset and LOS is generally not associated with a dementia, although VLOSLP are more likely to be associated with neurodegenerative processes. Antipsychotic medication is the mainstay of treatment and some psychosocial interventions may prove beneficial, but there is a lack of clinical trials focused on patients with onset in late-life. Response to treatment and outcomes tend to be better than among those with earlier onset, but special consideration should be given to biological and psychosocial factors related to the older age of patients

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.